[logo] HealthTree Foundation
search more_vert
close
person Sign In / Create Account

Joshua Brody, MD

CLL Specialist

Specialities: Chronic Lymphocytic Leukemia, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma

Spoken languages: English

Clinical Expertise

  • Leukemia
  • Chronic Lymphocytic Leukemia
  • Hodgkin Lymphoma
  • Non-Hodgkin Lymphoma

About

Joshua Brody, MD, is the Director of the Lymphoma Immunotherapy Program at The Tisch Cancer Institute at Mount Sinai and a faculty member of the Icahn Genomics Institute. Since joining Mount Sinai in 2011, he has developed a robust clinical program, as well as a translational Cancer Immunotherapy Lab which investigates basic and applied tumor immunology for the development of novel therapies, particularly for lymphomas, breast cancer, and head/neck cancer with results published in top-tier journals including Nature Medicine and Cancer Discovery.  Dr. Brody has pioneered a therapeutic vaccine approach—in situ vaccination—that induces anti-tumor immunity at the tumor site and can also cause regression of tumors throughout the body. He has also developed a way to use increase the power of immunotherapy drugs against treatment-resistant lymphomas by combining them with stem cell transplantation.  Recently, his group discovered a novel approach to improve immunotherapies by preventing a common escape mechanism that tumors use to evade CAR-T and bispecific antibody therapies.

Location

Mount Sinai Medical Center: 4306 Alton Rd 3rd Floor, Miami Beach, FL 33140, USA

newsletter icon

Get the latest thought leadership on your Marginal Zone Lymphoma delivered straight to your inbox

Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.